Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESGO 2021 | PARP inhibitor rechallenging in ovarian cancer

Isabelle Ray-Coquard • 23 Oct 2021
ESGO 2021
Gynecological Cancer Ovarian Cancer Olaparib

Isabelle Ray-Coquard, MD, PhD, Léon Bérard Center, Lyon, France, talks on PARP inhibitor rechallenge which may demonstrate a benefit in patients with platinum-sensitive relapsed ovarian cancer. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.

More from Isabelle Ray-Coquard

0:38
Personalized medicine for patients with gynecological sarcoma
Isabelle Ray-Coquard • 23 Oct 2021
1:08
Should 1L maintenance with PARP inhibitors be given to all patients with ovarian cancer?
Isabelle Ray-Coquard • 23 Oct 2021
1:16
KEYNOTE 826: pembrolizumab + chemo in patients with advanced cervical cancer
Isabelle Ray-Coquard • 1 Sep 2021
1:19
Testing HRD in the clinic
Isabelle Ray-Coquard • 1 Sep 2021

Related Videos

1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
0:46
Antibody-drug conjugates in gynecological cancers
Rebecca Porter • 8 Apr 2024
0:49
MITO-16a/MANGO-OV2a: plasma TF as a prognostic marker in ovarian cancer
Sergio Marchini • 8 Apr 2024
0:56
Mirvetuximab soravtansine with pembrolizumab in MSS endometrial cancer
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals